US 11,834,471 B2
Iron compositions and methods of making and using the same
Donald Jeffrey Keyser, Southlake, TX (US); Alvaro F. Guillem, Lantana, TX (US); and Richard A. Zager, Seattle, WA (US)
Assigned to Renibus Therapeutics, Inc., Southlake, TX (US)
Filed by RENIBUS THERAPEUTICS, INC., Southlake, TX (US)
Filed on Nov. 2, 2022, as Appl. No. 17/979,490.
Application 17/979,490 is a continuation of application No. 17/672,072, filed on Feb. 15, 2022.
Application 17/672,072 is a continuation of application No. 16/805,223, filed on Feb. 28, 2020, granted, now 11,292,813, issued on Apr. 5, 2022.
Claims priority of provisional application 62/812,028, filed on Feb. 28, 2019.
Prior Publication US 2023/0070012 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 23/00 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/409 (2006.01)
CPC C07H 23/00 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 31/409 (2013.01)] 4 Claims
 
1. An aqueous iron pharmaceutical composition comprising:
iron sucrose;
bicarbonate; and
a pharmaceutically acceptable aqueous carrier,
wherein the iron sucrose is present in pharmaceutically effective amount for providing a protective effect to a patient's kidney, the iron being present in both iron (II) and iron (Ill) form, the pharmaceutical composition has a pH greater than 9, a concentration of iron (II) of 0.05% w/v to 0.41% w/v, and the iron sucrose has a Mw according to GPC of between 33,000 and 38,000 Daltons.